peptide wiki

Chonluten

aka T-34 · EDG peptide · Glu-Asp-Gly · Bronchogen

Immune Modulator research-only

Mechanism

Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) short-peptide bioregulator developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It targets the bronchopulmonary system, where the Khavinson group reports it modulates gene expression in respiratory epithelium via direct peptide-DNA interaction in promoter regions. Evidence is limited to preclinical and small clinical studies from a single Russian research group; it is not FDA-approved and has no Western clinical validation.

Studied uses

Identification

CAS number75007-24-8
Molecular formulaC11H17N3O8
SequenceEDG
Typical doseNo established clinical dosing; vendor research protocols commonly cite 1-2 mg/day subcutaneous or sublingual
Half-lifeNot characterized in peer-reviewed pharmacokinetic literature; short-peptide bioregulators are presumed to clear rapidly (minutes)

Safety

Not FDA-approved for human therapeutic use. A Russian/Khavinson research peptide with little independent Western safety or efficacy data; sold grey-market for research use only. Not evaluated by WADA.

Vendors selling Chonluten

VendorSizePriceListed purityTrust
BioLongevity Labs 20 mg $69.97 96
Peptide Plugs 20 mg $50.00 89
Verified Peptides 20 mg $55.00 86

Research

Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, Marino A, Mironova E, Pulcini R, Robuffo I, Bologna G, Simeone P, Lanuti P, Guarnieri S, Trofimova S, Procopio AD, T, et al. · International journal of molecular sciences (2022) ·

This study evaluates the effects of five different peptides, the Epitalon ® tetrapeptide, the Vilon ® dipeptide, the Thymogen ® dipeptide, the Thymalin ® peptide complex, and the Chonluten ® tripeptide, as regulators of inflammatory and proliferative processes in the human monocytic THP-1, which is a human leukemia mon…

source →
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. · International journal of molecular sciences (2022) · review

Ultrashort peptides (USPs), consisting of 2-7 amino-acid residues, are a group of signaling molecules that regulate gene expression and protein synthesis under normal conditions in various diseases and ageing. USPs serve as a basis for the development of drugs with a targeted mechanism of action.

source →
Peptides: Prospects for Use in the Treatment of COVID-19
Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. · Molecules (Basel, Switzerland) (2020) · review

There is a vast practice of using antimalarial drugs, RAS inhibitors, serine protease inhibitors, inhibitors of the RNA-dependent RNA polymerase of the virus and immunosuppressants for the treatment of the severe form of COVID-19, which often occurs in patients with chronic diseases and older persons.

source →